CJC-1295 and Tesamorelin are both growth hormone-releasing hormone (GHRH) analogs studied for how they stimulate pulsatile growth hormone release. The central difference for anyone reading the literature is regulatory: Tesamorelin is an FDA-approved drug, while CJC-1295 is an unapproved research chemical with only early-phase human data. This article compares the two on mechanism, structure, half-life, and the published evidence. All material referenced is for in vitro research use only.
Direct answer: Both target the GHRH receptor to raise growth hormone and IGF-1. CJC-1295 (especially the DAC version) is engineered for a multi-day half-life but is not FDA approved. Tesamorelin is a daily, FDA-approved drug (Egrifta) for HIV-associated lipodystrophy with multiple phase 3 trials behind it.
How do GHRH analogs work?
Both CJC-1295 and Tesamorelin are agonists at the growth hormone-releasing hormone receptor (GHRHR) found on somatotroph cells of the anterior pituitary. Receptor binding activates the adenylyl cyclase, cAMP, and protein kinase A cascade, which drives synthesis and pulsatile release of growth hormone (GH). Circulating GH in turn stimulates the liver to produce insulin-like growth factor 1 (IGF-1). Native GHRH(1-44) has a half-life of only a few minutes because the enzyme dipeptidyl peptidase-IV (DPP-IV) cleaves its N-terminus. Both analogs are deliberately engineered to resist this cleavage, which is the design problem each one solves in a different way. This is established GHRH pharmacology, supported across the clinical reviews of both compounds rather than a single primary paper.
What is CJC-1295?
CJC-1295 is a synthetic analog built on a modified GHRH(1-29) backbone, often called "mod GRF 1-29," with amino acid substitutions that resist DPP-IV degradation. The most studied variant, CJC-1295 with DAC (Drug Affinity Complex), adds a maleimido group that forms a covalent bond to serum albumin in the bloodstream, dramatically extending circulation time. A separate non-DAC version lacks this albumin binder and has a much shorter half-life of roughly 30 minutes. The structural specifics are drawn from review and developer literature rather than a single peer-reviewed primary paper, so they are best read as reported chemistry. CJC-1295 was developed by ConjuChem and is not approved by the FDA for any human use.
What does the human research on CJC-1295 show?
The foundational human study is Teichman and colleagues (2006) in the Journal of Clinical Endocrinology & Metabolism, which ran two randomized, placebo-controlled, double-blind ascending-dose trials of CJC-1295 with DAC in healthy adults. A single subcutaneous injection produced dose-dependent increases in mean plasma GH of roughly 2- to 10-fold lasting at least six days, and increases in IGF-1 of about 1.5- to 3-fold lasting 9 to 11 days. The authors estimated a half-life of 5.8 to 8.1 days, and with repeated dosing mean IGF-1 stayed above baseline up to 28 days. No serious adverse reactions were reported in that work. This remains an early-phase pharmacology program, not the large multi-trial record that supports an approved drug (Teichman et al., 2006).
What is Tesamorelin?
Tesamorelin is a stabilized analog of full-length GHRH(1-44). Its key modification is a trans-3-hexenoic acid group attached to the N-terminal tyrosine, which sterically blocks DPP-IV cleavage while preserving receptor binding, allowing once-daily dosing. Unlike CJC-1295, Tesamorelin is an approved pharmaceutical: the FDA approved it under the brand name Egrifta on November 10, 2010, as the first treatment to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Its manufacturer is Theratechnologies. Because it is an approved drug studied in registered clinical trials, the Tesamorelin evidence base is substantially deeper and more rigorous than the research-chemical literature on CJC-1295.
What does the human research on Tesamorelin show?
Tesamorelin is supported by multiple phase 3 randomized controlled trials. Falutz and colleagues (2007) reported in the New England Journal of Medicine that tesamorelin 2 mg daily produced a selective reduction in visceral adipose tissue with improved lipid profile and no significant adverse effect on glucose measures. A pooled phase 3 analysis (Falutz et al., 2010) found visceral fat fell by roughly 15 percent versus placebo at 26 weeks, with benefit requiring continued treatment. Later trials extended the work to liver fat: Stanley and colleagues (2014, JAMA) reported reduced visceral and liver fat, and a 2019 Lancet HIV trial reported a meaningful reduction in hepatic fat fraction in HIV-associated fatty liver disease.
CJC-1295 vs Tesamorelin: side-by-side comparison
| Dimension | CJC-1295 (with DAC) | Tesamorelin (Egrifta) |
|---|---|---|
| Backbone | Modified GHRH(1-29) + DAC albumin binder | Stabilized GHRH(1-44) + hexenoic acid group |
| Receptor target | GHRH receptor (pituitary) | GHRH receptor (pituitary) |
| Half-life | ~5.8 to 8.1 days (DAC); ~30 min (non-DAC) | Short parent peptide, dosed once daily |
| Human evidence | One early-phase program (Teichman 2006) | Multiple phase 3 RCTs (Falutz, Stanley) |
| Regulatory status | Not FDA approved, research chemical | FDA approved drug (Nov 10, 2010) |
What does this comparison mean for research framing?
The two peptides illustrate two ends of the evidence spectrum. Tesamorelin has cleared the regulatory bar with replicated phase 3 data and a defined approved indication. CJC-1295 has a single notable early-phase human pharmacology study and no approval, which is why it remains a research compound. For laboratory work, the meaningful contrasts are half-life design, the depth of the human record, and regulatory status, not any suggestion of interchangeable use. Research suppliers, including Next Level Labs, offer these peptides strictly for in vitro and laboratory research, not for human consumption.
Where can researchers find related materials?
NLL stocks GHRH-axis research peptides including CJC-1295 + Ipamorelin, CJC-1295 with DAC, and a Tesamorelin + Ipamorelin blend. Independent third-party purity data per lot is published in the Lab Reports library, and research-use questions are answered on the FAQ page.
SOURCES
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. (randomized human trials)
- Falutz J, et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370. (phase 3 RCT)
- Falutz J, et al. "Effects of tesamorelin on visceral fat (pooled phase 3 analysis)." Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304. (pooled phase 3 analysis)
- Stanley TL, Feldpausch MN, Oh J, et al. "Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation: A Randomized Clinical Trial." JAMA. 2014;312(4):380-389. (RCT)
- Stanley TL, Fourman LT, Feldpausch MN, et al. "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial." Lancet HIV. 2019;6(12):e821-e830. (RCT)
- U.S. Food and Drug Administration. Approval of Egrifta (tesamorelin), November 10, 2010. (regulatory record)
For in vitro research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any condition. This article summarizes published research and is not medical advice.